Persona
COLLO LUIGIA RINALDA
Docenti di ruolo di IIa fascia
Curriculum Vitae
CURRICULUM VITAE
Luigia (Ginetta) Collo, M.D.
PERSONAL INFORMATION
Place and date of birth: Brescia, Italy, 21-08-1959
Nationality: Italian
Address: via Malvestiti 18, 25123 Brescia, Italy.
e-mail: luigia.collo@unibs.it
Spoken languages: Italian, English, French.
PRESENT POSITION: Assistant Professor Division of Pharmacology, Adjunct Professor of Pharmacology University of Brescia, Brescia, Italy.
EDUCATION
1985: Medical Degree, Summa cum Laude, University of Brescia, Italy.
1989: Specialisation in Obstetrics and Gynaecology, University of Brescia, Italy.
PROFESSIONAL EXPERIENCE
• January-December 2013: Visiting Scientist (Congedo straordinario per studio e ricerca) Department of Biomedicine, Laboratory of Embryology and Stem Cell Biology, Prof. Verdon Taylor, University of Basel, Switzerland.
• July-August 2008: Visiting Scientist Department of Stem Cell and Regenerative Biology, Laboratory of Prof. Lee Rubin, Harvard Stem Cell Institute, Cambridge, US.
• 2005-2018: Assistant Professor Division of Pharmacology; Department of Molecular and Translational Medicine, University of Brescia, Italy.
• 2005-2018: Adjunct Professor of Pharmacology, University of Brescia, Italy.
• 2002-2004: Senior Scientist, Lab Head; Department of Biomedical Sciences and Biotechnologies, Division of Pharmacology, University of Brescia, Italy.
• 1999-2001: Maternity leave
• 1995-1998: Senior Scientist, Department of Molecular Biology, Glaxo Institute for Molecular Biology, Geneva, Switzerland.
• 1994-1995: Scientist, Department of Morphology, University of Geneva, Switzerland.
• 1990-1994: Postdoctoral Research Associate, Department of Cell Biology, The Scripps Research Institute, La Jolla, California.
• 1988-1990: Adjunct Professor at the School of Obstetric, University of Brescia, Italy.
• 1985-1990: Resident MD, Obstetric and Gynaecology Department, University of Brescia, Italy.
• 1985-1990: Research Associate Laboratory of Biotechnology, Dipartimento Materno Infantile, University of Brescia, Italy.
GRANTS, CONTRACTS AND AWARDS
• 2018-2019: Co-investigator with professor Verdon Taylor (University of Basel), grant from Hoffman La Roche for the project “Elucidating the molecular pathophysiology of GCase/α-synuclein dysfunction in PD with hPSCs”.
• 2017: Recipient of a contract from Institut de Recherche Pierre Fabre for the project: “Study of the effects of a Pierre Fabre D3 receptor antagonist on structural plasticity in human iPSC derived dopaminergic neurons”.
• 2012-2016: Co-investigator with professor Verdon Taylor (University of Basel), grant from Hoffman La Roche for the project “IPS derived dopaminergic neurons as human model to study novel therapeutics for Parkinson’s Disease”.
• 2015: Recipient of a contract from Institute des Recherches Servier for the project: “Characterisation of the neuroprotective properties of piribedil in human, dopaminergic iPS cell-derived neurons”.
• 2013-2014: Recipient of a contract from UCB Pharma for the project: “Study of the effect of a NR2B NAM in primary cultures of mouse mesencephalic dopaminergic neurons”.
• 2013-2015: Recipient of a contract from BiofiNext Brescia for the project: “Generation of dopaminergic neurons from iPS cells of patients with parkinsonian neurodegenerative disorders”.
• 2011-2013: Co-investigator in a project granted from the Camillo Golgi Foundation of Brescia: “Neuronal lineage differentiation of Induced Pluripotent Stem Cells (iPS) from patients affected by Mood Disorders for pharmacological studies”.
• 2011-2013: PRIN 2009 grant from the Ministry of Education, University and Research of Italy (MIUR), (Responsabile di Unità), “Role of the dopamine and nicotinic acetylcholine receptors in structural plasticity induced by nicotine on dopaminergic neurons”. Coordinator of the project Prof. Michele Zoli.
• 2010-2013: Component of a project granted from Italian Institute of Technology: “Enhancing structural neuroplasticity of dopamine neurons in Parkinson’s disease: Role of dopamine D3 and acetylcholine nicotinic receptor interaction”.
• 2009-2011: Component of Michael J. Fox Foundation grant for Research on Parkinson Disease to Prof. C. Missale.
• 2002-2005: Co-investigator in a GlaxoSmithKline (Verona, Italy) sponsored grant “Differentiation of mouse precursor skin stem cell into neuronal phenotype: a new approach for pharmacologic studies”.
• 1992-1994: Component of a R01 NIH grant on “New class of tumor associated antigens” to Dr. Vito Quaranta, The Scripps Research Institute, La Jolla, CA.
• 1990-1992: Recipient of a fellowship from the Camillo Golgi Foundation of Brescia, Italy (2 Years).
• 1987-1990: Fellowship (3 Years) from Regione Lombardia, Italy.
PARTICIPATION TO SCIENTIFIC BOARDS
• 2017-2020: Member of the ECNP (European Neuropsychopharmacology) Scientific Advisory Panel.
• 2018: Member of the committee for the PhD Course final examination “Neuroscienze, Scienze Psicologiche e Psichiatriche”, University of Verona, Italy.
• 2017: Expert external evaluator for two PhD thesis of the International PhD School in Neuroscience, University of Catania, Italy.
• 2016: Member of the committee for the PhD School final examination in Biological Molecular Science, University of Milan, Italy.
• 2014: Member of the committee for the PhD School final examination in Biomedicina Traslazionale, University of Verona, Italy.
• 2012-2015: Member of the board for the PhD School in Neuroscience, University of Brescia, Italy.
• 2011-2014: Member of the board for the PhD School in Neuroscience, University of Brescia, Italy.
CURRENT COLLABORATIONS
• Professor Verdon Taylor, Embryology and Stem Cell Biology, Department of Biomedicine University of Basel (CH).
• Dr. Tilo Kunath, MRC, Centre for Regenerative Medicine, University of Edimburgh (UK).
• Dr. Marc Millan, Dept. Neuropharmacology, Institute des Recherches Servier, Paris (F).
• Dr. Ravi Jagasia, Roche Pharma Research & Early Development, Hoffmann-La Roche, Basel (CH).
• Professor Christian Chiamulera, Dept. Diagnostic & Public Health, University of Verona (I).
• Professor Paolo Barone and Professor Maria Teresa Pellecchia, University of Salerno (I)
• Professor Michele Zoli, Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze, Università di Modena e Reggio Emilia (I).
• Dr. Corrado Corti, Eurac Research, Bolzano (I)
PRESENT SCIENTIFIC INTERESTS
• Use human inducible pluripotent stem cells as a new approach to study the molecular and cellular mechanisms of neurodegeneration, psychiatric diseases and dependence as well as a new system to study the pharmacological effects of new drug candidates in vitro.
• Cellular e molecular mechanisms of neurodegeneration and neuroregeneration relevant for Parkinson’s Disease using iPSC derived dopaminergic neurons and primary cellular culture of mesencephalic dopaminergic neurons from mouse embryo.
• Characterization of cellular and molecular mechanism of action (MOA) of pharmacological agents relevant for the treatment of neurological and psychiatric disorders related to dopamine system impairment such as Parkinson’s Disease and Depression.
PREVIOUS SCIENTIFIC INTERESTS
• Identification of new integrins and study of their role in cell differentiation, maturation and migration, in vitro and during mouse embryo development, in particular on excitable tissues: neurons and muscle cells.
• Identification, expression mapping and cellular functional analysis of P2X ion channels in mammals, with a focus on central and peripheral nervous system, and on immune systems.
THEACHING ACTIVITY
• 2017-2018, annual course of Pharmacology to medical students and to paramedics, University of Brescia.
• 2002 - 2017, annual course of Pharmacology to paramedics and technologists, University of Brescia.
• 1988 – 1990, annual course of Biology & Genetics to nurse-midwife, University Hospital of Brescia, Italy.
• 2002 – 2018, supervision of internship and thesis preparation of graduate students of Medical Biotechnology and of Pharmaceutical Chemistry, and PhD students.
MANUSCRIPT REFEREE:
• Brain Research
• British Journal of Pharmacology
• European Neuropsychopharmacology
• Journal of Neurochemistry
• Neuropsychopharmacology
INVITED TALKS (SELECTION)
• 2017, 25-28 October: Congresso Nazionale della Società Italiana di Farmacologia, Rimini, Italy. Talk title: “Ketamine induced structural plasticity in human iPCS-derived dopaminergic neurons”.
• 2017, 17 March: UNISTEM DAY, The long and fascinating trip of stem cell research, Brescia, Italy. Talk title: “Cosa sono e a cosa servono le cellule staminali”.
• 2015, 27-30 October: Congresso Nazionale della Società Italiana di Farmacologia, Napoli, Italy. Talk title: ”Nicotine produces structural plasticity in dopaminergic neurons: evidence from mouse neuronal cultures and human IPSC-derived neurons”.
• 2015, 29 August- 1 September: 28th ECNP Congress, Amsterdam, Holland. Talk title: “mTOR controls structural plasticity of dopaminergic neurons: implication in the actions of ketamine”.
• 2015, 19-22 May: 12eme Colloque de la Société des Neuroscience. Montpellier, France. Talk title: “mTOR activation in dopaminergic neurons: critical role in drug addiction”.
• 2013, 14-17 December: 22nd ISFN annual Meeting and Binational Italian-Israeli Neuroscience Meeting. Eilat, Israele. Talk title: ”Testing the effect of dopamine agonists and of drugs of addiction on structural plasticity of dopaminergic neurons: translation from mouse primary cell culture to human iPSC-derived neurons”.
• 2013 September 9th: University of Basel/Roche Collaboration in Neuroscience. Talk title: “iPS cell-derived dopaminergic neurons as human model to study novel therapeutics for Parkinson Disease”.
• 2013, 24-28 May: Dopamine 2013, Alghero, Italy. Talk title: “Critical role of dopamine D3 receptor in structural plasticity generated by exposure to drugs of addiction in mesencephalic dopaminergic neurons”.
• 2008, 20-22 November: XXXV Congresso Nazionale LIMPE “Approccio razionale ai disturbi del movimento”. Salerno, Italy. Talk title: “Effetti neurotrofici dei farmaci agonisti preferenziali D3 sui neuroni mesencefalici: implicazioni terapeutiche per la Malattia di Parkinson”.
MEMBERSHIPS
Member of the European College of Neuropsychopharmacology.
Member of the Society of Neuroscience (US).
Member of the Italian Society of Pharmacology.
MEMBERSHIP
Member of the Society of Neuroscience (US).
PUBBLICATIONS (* corresponding author)
• Collo, G.*, Cavalleri, L., Bono, F., Mora, C., Fedele, S., Invernizzi, R.W., Gennarelli M., Piovani G., Kunath T., Millan M.J., Merlo Pich E., Spano PF. (2017) Ropinirole and pramipexole promote structural plasticity in human iPSC-derived dopaminergic neurons via BDNF and mTOR signaling. Neural Plasticity. Volume 2018, Article ID 4196961,doi.org/10.1155/2018/4196961. 2018.
• Cavalleri L., Merlo Pich E., Millan M.J., Chiamulera C., Kunath T., Spano PF., Collo G.* Ketamine enhances structural plasticity in mouse-mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling”. Molecular Psychiatry. Nov 21. doi: 10.1038/mp.2017.241. 2018.
• Fedele S., Collo G., Behr K., Bischofberger J., Muller S., Kunath T., Christensen K., Gundner A.L., Graf M., Jagasia R., Taylor V. Expansion of human midbrain floor plate progenitors from induced pluripotent stem cells increases dopaminergic neurons differentiation potential. Scientific Reports. 7: 6036. 2017.
• Merlo Pich E. Collo G. Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective drugs. European Neuropsychopharmacology. 25: 1437-1447. 2015.
• Collo G.*, Cavalleri L., Spano P. Structural plasticity in mesencephalic dopaminergic neurons produced by drugs of abuse: critical role of BDNF and dopamine. Front Pharmacol. Nov 25; 5:259. 2014.
• Le Foll B., Collo G., Rabiner E.A., Boileau I., Merlo Pic E., Sokoloff P. Dopamine D3 ligands for drug addiction treatment: update on recent finding. Progress in Brain Research, 211:255-75, 2014.
• Collo G.*, Bono F., Cavalleri L., Plebani L., Mitola S., Pich E.M., Millan M.J., Zoli M., Maskos U., Spano P., Missale C. Nicotine-induced structural plasticity in mesencephalic dopaminergic neurons is mediated by dopamine D3 receptors and Akt-mTORC1 signaling. Molecular Pharmacology, vol. 83, p. 1176-1189, 2013.
• Collo G.*, Bono F., Cavalleri L., Plebani L., Merlo Pich E., Millan M.J., Spano P.F., Missale C. Pre-synaptic dopamine D3 receptor mediates cocaine-induced structural plasticity in mesencephalic dopaminergic neurons via ERK and Akt pathways. J. Neurochem. 120:765-778, 2012.
• Bellucci A, Navarria L, Falarti E, Zaltieri M, Bono F, Collo G, Spillantini MG, Missale C, Spano PF. Redistribution of DAT/α-synuclein complexes visualized by "in situ" proximity ligation assay in transgenic mice modelling early Parkinson's disease. PLoS One 6(12):e27959, 2011.
• Fiorentini C, Mattanza C, Collo G, Savoia P, Spano PF., Missale C. The tyrosine phosphatase SHP-2 interacts with the dopamina D1 receptor and triggers D1-mediated ERK signaling in striatal neurons. J. Neurochem. 117:253-63, 2011.
• Missale C, Fiorentini C, Collo G, Spano PF. The neurobiology of dopamine receptors: evolution from the dual concept to heterodimers complexes. J Recept Signal Transduct Res. 30: 347-54, 2010.
• Collo G*, Gregorini A, Missale C, Spano PF. D3 receptor involvement in neurotrophic effects of amphetamine and cocaine on mesencephalic dopaminergic neurons. European Neuropsychopharmacology 18:S243-S244. 2008.
• Collo G*, Zanetti S, Missale C, Spano PF. Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation Eur. J. Neurosci. 28:1231-1240, 2008.
• Bellucci A, Collo G, Sarnico I, Battistin L, Missale C, Spano PF. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation. J. Neurochem. 106:560-77. 2008.
• Collo G*, Goffi F, Merlo Pich E, Balzelli P, Benfenati F, Spano PF. Immature neuronal phenotype derived from mouse skin precursor cells differentiated in vitro. Brain Res.1109:32-36. 2006.
• Missale C, Fiorentini C, Busi C, Collo G, Spano PF. The NMDA/D1 receptor complex as a new target in drug development. Curr Top Med Chem. 6:801-808. 2006.
• Fiorentini C, Rizzetti MV, Busi C, Bontempi S, Collo G, Spano PF, Missale C. Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat. Mol. Pharmacol. 69:805-812. 2005.
• Mutini C, Falzoni S, Ferrari D, Chiozzi P, Morelli A, Baricordi OR, Collo G, Ricciardi-Castagnoli P, Di Virgilio F. Mouse dendritic cells express the P2X7 purinergic receptor: characterization and possible participation in antigen presentation. Journal of Immunology 163: 1958-65. 1999.
• Collo G, Pepper MS. Endothelial cell integrin alpha5beta1 expression is modulated by cytokines and during migration in vitro. Journal of Cell Science 112: 569-78. 1999.
• Buell G, Chessell IP, Michel AD, Collo G, Salazzo M, Herren S, Gretener D, Grahames C, Kaur R, Kosco-Vilbois MH, Humphrey PP. Blockade of human P2X7 receptor function with a monoclonal antibody. Blood 92: 3521-8. 1998.
• Brancaccio M, Cabodi S, Belkin AM, Collo G, Koteliansky VE, Tomatis D, Altruda F, Silengo L, Tarone G. Differential onset of expression of alpha7 and beta1D integrins during mouse heart and skeletal muscle development. Cell Adhesion and Commununication 5: 193-205. 1998.
• Russo S, Tomatis D, Collo G, Tarone G, Tato F. Myogenic conversion of NIH3T3 cells by exogenous MyoD family members: dissociation of terminal differentiation from myotube formation. Journal of Cell Science 111: 691-700. 1998.
• Ferrari D, Chiozzi P, Falzoni S, Dal Susino M, Collo G, Buell G, Di Virgilio F. ATP mediated cytotoxicity in microglial cells. Neuropharmacology 36: 1295-301. 1997.
• Collo G, Neidhart S, Kawashima E, Kosco-Vilbois M, North RA, Buell G. Tissue distribution of the P2X7 receptor. Neuropharmacology 36: 1277-83. 1997.
• Chiozzi P, Sanz JM, Ferrari D, Falzoni S, Aleotti A, Buell GN, Collo G, Di Virgilio F. Spontaneous cell fusion in macrophage cultures expressing high levels of the P2Z/P2X7 receptor. Journal Cell Biology 138: 697-706, 1997.
• Rassendren F. Buell GN. Virginio C. Collo G. North RA. Surprenant A. The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. Journal Biological Chemistry 272: 5482-6, 1997.
• Velling T. Collo G. Sorokin L. Durbeej M. Zhang H. Gullberg D. Distinct alpha7A-beta1 and alpha7B-beta1 integrin expression patterns during mouse development: alpha7A is restricted to skeletal muscle but alpha7B is expressed in striated muscle, vasculature, and nervous system. Developmental Dynamics 207: 355-71, 1996.
• Buell G. Collo G. Rassendren F. P2X receptors: an emerging channel family. European Journal of Neuroscience 8: 2221-8, 1996.
• Collo G. North RA. Kawashima E. Merlo-Pich E. Neidhart S. Surprenant A. Buell G. Cloning of P2X5 and P2X6 receptors and the distribution and properties of an extended family of ATP-gated ion channels. Journal of Neuroscience 16: 2495-507, 1996.
• Buell G. Michel AD. Lewis C. Collo G. Humphrey PP. Surprenant A. P2X1 receptor activation in HL60 cells. Blood 87: 2659-64, 1996.
• Buell G. Lewis C. Collo G. North RA. Surprenant A. An antagonist-insensitive P2X receptor expressed in epithelia and brain. EMBO Journal.15: 55-6, 1996.
• Collo G., Domanico S., Klier, G., and Quaranta, V. Gradient of integrin α6A expession in the myocardium during early heart development. Cell Adhesion and Communication 3: 101-13, 1995.
• Collo, G., Starr, L., and Quaranta, V. A new isoform of the laminin receptor α7β1 is developmentally regulated in skeletal muscle. Journal of Biological Chemistry 268: 19019-19024, 1993.
• Tamura, R.N., Cooper, H.M., Collo, G. and Quaranta, V. Cell-type specific integrin variants with alternative chain cytoplasmic domain. P. Natl. Acad. Sci. 88: 10183-10187, 1991.
• Quaranta V, Collo G, Rozzo C, Starr L, Gaietta G and Tamura RN The integrin alpha6beta4 in epithelial and carcinoma cells, In: Integrins: The Biological Problems Eds. Y Takada, CRC Press (Boca Raton) 147-176, 1994.
• Quaranta V, Tamura RN, Collo G, Cooper HM, Hormia M, Rozzo C, Gaietta G and Starr L. Distinctive functions of alpha6beta4 and other integrins in epithelial cells, In: Integrins: Molecular and Biological Responses to the Extracellular Matrix Eds. D Cheresh, M RP, Academic Press (San Diego) 141-161, 1994.
Luigia (Ginetta) Collo, M.D.
PERSONAL INFORMATION
Place and date of birth: Brescia, Italy, 21-08-1959
Nationality: Italian
Address: via Malvestiti 18, 25123 Brescia, Italy.
e-mail: luigia.collo@unibs.it
Spoken languages: Italian, English, French.
PRESENT POSITION: Assistant Professor Division of Pharmacology, Adjunct Professor of Pharmacology University of Brescia, Brescia, Italy.
EDUCATION
1985: Medical Degree, Summa cum Laude, University of Brescia, Italy.
1989: Specialisation in Obstetrics and Gynaecology, University of Brescia, Italy.
PROFESSIONAL EXPERIENCE
• January-December 2013: Visiting Scientist (Congedo straordinario per studio e ricerca) Department of Biomedicine, Laboratory of Embryology and Stem Cell Biology, Prof. Verdon Taylor, University of Basel, Switzerland.
• July-August 2008: Visiting Scientist Department of Stem Cell and Regenerative Biology, Laboratory of Prof. Lee Rubin, Harvard Stem Cell Institute, Cambridge, US.
• 2005-2018: Assistant Professor Division of Pharmacology; Department of Molecular and Translational Medicine, University of Brescia, Italy.
• 2005-2018: Adjunct Professor of Pharmacology, University of Brescia, Italy.
• 2002-2004: Senior Scientist, Lab Head; Department of Biomedical Sciences and Biotechnologies, Division of Pharmacology, University of Brescia, Italy.
• 1999-2001: Maternity leave
• 1995-1998: Senior Scientist, Department of Molecular Biology, Glaxo Institute for Molecular Biology, Geneva, Switzerland.
• 1994-1995: Scientist, Department of Morphology, University of Geneva, Switzerland.
• 1990-1994: Postdoctoral Research Associate, Department of Cell Biology, The Scripps Research Institute, La Jolla, California.
• 1988-1990: Adjunct Professor at the School of Obstetric, University of Brescia, Italy.
• 1985-1990: Resident MD, Obstetric and Gynaecology Department, University of Brescia, Italy.
• 1985-1990: Research Associate Laboratory of Biotechnology, Dipartimento Materno Infantile, University of Brescia, Italy.
GRANTS, CONTRACTS AND AWARDS
• 2018-2019: Co-investigator with professor Verdon Taylor (University of Basel), grant from Hoffman La Roche for the project “Elucidating the molecular pathophysiology of GCase/α-synuclein dysfunction in PD with hPSCs”.
• 2017: Recipient of a contract from Institut de Recherche Pierre Fabre for the project: “Study of the effects of a Pierre Fabre D3 receptor antagonist on structural plasticity in human iPSC derived dopaminergic neurons”.
• 2012-2016: Co-investigator with professor Verdon Taylor (University of Basel), grant from Hoffman La Roche for the project “IPS derived dopaminergic neurons as human model to study novel therapeutics for Parkinson’s Disease”.
• 2015: Recipient of a contract from Institute des Recherches Servier for the project: “Characterisation of the neuroprotective properties of piribedil in human, dopaminergic iPS cell-derived neurons”.
• 2013-2014: Recipient of a contract from UCB Pharma for the project: “Study of the effect of a NR2B NAM in primary cultures of mouse mesencephalic dopaminergic neurons”.
• 2013-2015: Recipient of a contract from BiofiNext Brescia for the project: “Generation of dopaminergic neurons from iPS cells of patients with parkinsonian neurodegenerative disorders”.
• 2011-2013: Co-investigator in a project granted from the Camillo Golgi Foundation of Brescia: “Neuronal lineage differentiation of Induced Pluripotent Stem Cells (iPS) from patients affected by Mood Disorders for pharmacological studies”.
• 2011-2013: PRIN 2009 grant from the Ministry of Education, University and Research of Italy (MIUR), (Responsabile di Unità), “Role of the dopamine and nicotinic acetylcholine receptors in structural plasticity induced by nicotine on dopaminergic neurons”. Coordinator of the project Prof. Michele Zoli.
• 2010-2013: Component of a project granted from Italian Institute of Technology: “Enhancing structural neuroplasticity of dopamine neurons in Parkinson’s disease: Role of dopamine D3 and acetylcholine nicotinic receptor interaction”.
• 2009-2011: Component of Michael J. Fox Foundation grant for Research on Parkinson Disease to Prof. C. Missale.
• 2002-2005: Co-investigator in a GlaxoSmithKline (Verona, Italy) sponsored grant “Differentiation of mouse precursor skin stem cell into neuronal phenotype: a new approach for pharmacologic studies”.
• 1992-1994: Component of a R01 NIH grant on “New class of tumor associated antigens” to Dr. Vito Quaranta, The Scripps Research Institute, La Jolla, CA.
• 1990-1992: Recipient of a fellowship from the Camillo Golgi Foundation of Brescia, Italy (2 Years).
• 1987-1990: Fellowship (3 Years) from Regione Lombardia, Italy.
PARTICIPATION TO SCIENTIFIC BOARDS
• 2017-2020: Member of the ECNP (European Neuropsychopharmacology) Scientific Advisory Panel.
• 2018: Member of the committee for the PhD Course final examination “Neuroscienze, Scienze Psicologiche e Psichiatriche”, University of Verona, Italy.
• 2017: Expert external evaluator for two PhD thesis of the International PhD School in Neuroscience, University of Catania, Italy.
• 2016: Member of the committee for the PhD School final examination in Biological Molecular Science, University of Milan, Italy.
• 2014: Member of the committee for the PhD School final examination in Biomedicina Traslazionale, University of Verona, Italy.
• 2012-2015: Member of the board for the PhD School in Neuroscience, University of Brescia, Italy.
• 2011-2014: Member of the board for the PhD School in Neuroscience, University of Brescia, Italy.
CURRENT COLLABORATIONS
• Professor Verdon Taylor, Embryology and Stem Cell Biology, Department of Biomedicine University of Basel (CH).
• Dr. Tilo Kunath, MRC, Centre for Regenerative Medicine, University of Edimburgh (UK).
• Dr. Marc Millan, Dept. Neuropharmacology, Institute des Recherches Servier, Paris (F).
• Dr. Ravi Jagasia, Roche Pharma Research & Early Development, Hoffmann-La Roche, Basel (CH).
• Professor Christian Chiamulera, Dept. Diagnostic & Public Health, University of Verona (I).
• Professor Paolo Barone and Professor Maria Teresa Pellecchia, University of Salerno (I)
• Professor Michele Zoli, Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze, Università di Modena e Reggio Emilia (I).
• Dr. Corrado Corti, Eurac Research, Bolzano (I)
PRESENT SCIENTIFIC INTERESTS
• Use human inducible pluripotent stem cells as a new approach to study the molecular and cellular mechanisms of neurodegeneration, psychiatric diseases and dependence as well as a new system to study the pharmacological effects of new drug candidates in vitro.
• Cellular e molecular mechanisms of neurodegeneration and neuroregeneration relevant for Parkinson’s Disease using iPSC derived dopaminergic neurons and primary cellular culture of mesencephalic dopaminergic neurons from mouse embryo.
• Characterization of cellular and molecular mechanism of action (MOA) of pharmacological agents relevant for the treatment of neurological and psychiatric disorders related to dopamine system impairment such as Parkinson’s Disease and Depression.
PREVIOUS SCIENTIFIC INTERESTS
• Identification of new integrins and study of their role in cell differentiation, maturation and migration, in vitro and during mouse embryo development, in particular on excitable tissues: neurons and muscle cells.
• Identification, expression mapping and cellular functional analysis of P2X ion channels in mammals, with a focus on central and peripheral nervous system, and on immune systems.
THEACHING ACTIVITY
• 2017-2018, annual course of Pharmacology to medical students and to paramedics, University of Brescia.
• 2002 - 2017, annual course of Pharmacology to paramedics and technologists, University of Brescia.
• 1988 – 1990, annual course of Biology & Genetics to nurse-midwife, University Hospital of Brescia, Italy.
• 2002 – 2018, supervision of internship and thesis preparation of graduate students of Medical Biotechnology and of Pharmaceutical Chemistry, and PhD students.
MANUSCRIPT REFEREE:
• Brain Research
• British Journal of Pharmacology
• European Neuropsychopharmacology
• Journal of Neurochemistry
• Neuropsychopharmacology
INVITED TALKS (SELECTION)
• 2017, 25-28 October: Congresso Nazionale della Società Italiana di Farmacologia, Rimini, Italy. Talk title: “Ketamine induced structural plasticity in human iPCS-derived dopaminergic neurons”.
• 2017, 17 March: UNISTEM DAY, The long and fascinating trip of stem cell research, Brescia, Italy. Talk title: “Cosa sono e a cosa servono le cellule staminali”.
• 2015, 27-30 October: Congresso Nazionale della Società Italiana di Farmacologia, Napoli, Italy. Talk title: ”Nicotine produces structural plasticity in dopaminergic neurons: evidence from mouse neuronal cultures and human IPSC-derived neurons”.
• 2015, 29 August- 1 September: 28th ECNP Congress, Amsterdam, Holland. Talk title: “mTOR controls structural plasticity of dopaminergic neurons: implication in the actions of ketamine”.
• 2015, 19-22 May: 12eme Colloque de la Société des Neuroscience. Montpellier, France. Talk title: “mTOR activation in dopaminergic neurons: critical role in drug addiction”.
• 2013, 14-17 December: 22nd ISFN annual Meeting and Binational Italian-Israeli Neuroscience Meeting. Eilat, Israele. Talk title: ”Testing the effect of dopamine agonists and of drugs of addiction on structural plasticity of dopaminergic neurons: translation from mouse primary cell culture to human iPSC-derived neurons”.
• 2013 September 9th: University of Basel/Roche Collaboration in Neuroscience. Talk title: “iPS cell-derived dopaminergic neurons as human model to study novel therapeutics for Parkinson Disease”.
• 2013, 24-28 May: Dopamine 2013, Alghero, Italy. Talk title: “Critical role of dopamine D3 receptor in structural plasticity generated by exposure to drugs of addiction in mesencephalic dopaminergic neurons”.
• 2008, 20-22 November: XXXV Congresso Nazionale LIMPE “Approccio razionale ai disturbi del movimento”. Salerno, Italy. Talk title: “Effetti neurotrofici dei farmaci agonisti preferenziali D3 sui neuroni mesencefalici: implicazioni terapeutiche per la Malattia di Parkinson”.
MEMBERSHIPS
Member of the European College of Neuropsychopharmacology.
Member of the Society of Neuroscience (US).
Member of the Italian Society of Pharmacology.
MEMBERSHIP
Member of the Society of Neuroscience (US).
PUBBLICATIONS (* corresponding author)
• Collo, G.*, Cavalleri, L., Bono, F., Mora, C., Fedele, S., Invernizzi, R.W., Gennarelli M., Piovani G., Kunath T., Millan M.J., Merlo Pich E., Spano PF. (2017) Ropinirole and pramipexole promote structural plasticity in human iPSC-derived dopaminergic neurons via BDNF and mTOR signaling. Neural Plasticity. Volume 2018, Article ID 4196961,doi.org/10.1155/2018/4196961. 2018.
• Cavalleri L., Merlo Pich E., Millan M.J., Chiamulera C., Kunath T., Spano PF., Collo G.* Ketamine enhances structural plasticity in mouse-mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling”. Molecular Psychiatry. Nov 21. doi: 10.1038/mp.2017.241. 2018.
• Fedele S., Collo G., Behr K., Bischofberger J., Muller S., Kunath T., Christensen K., Gundner A.L., Graf M., Jagasia R., Taylor V. Expansion of human midbrain floor plate progenitors from induced pluripotent stem cells increases dopaminergic neurons differentiation potential. Scientific Reports. 7: 6036. 2017.
• Merlo Pich E. Collo G. Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective drugs. European Neuropsychopharmacology. 25: 1437-1447. 2015.
• Collo G.*, Cavalleri L., Spano P. Structural plasticity in mesencephalic dopaminergic neurons produced by drugs of abuse: critical role of BDNF and dopamine. Front Pharmacol. Nov 25; 5:259. 2014.
• Le Foll B., Collo G., Rabiner E.A., Boileau I., Merlo Pic E., Sokoloff P. Dopamine D3 ligands for drug addiction treatment: update on recent finding. Progress in Brain Research, 211:255-75, 2014.
• Collo G.*, Bono F., Cavalleri L., Plebani L., Mitola S., Pich E.M., Millan M.J., Zoli M., Maskos U., Spano P., Missale C. Nicotine-induced structural plasticity in mesencephalic dopaminergic neurons is mediated by dopamine D3 receptors and Akt-mTORC1 signaling. Molecular Pharmacology, vol. 83, p. 1176-1189, 2013.
• Collo G.*, Bono F., Cavalleri L., Plebani L., Merlo Pich E., Millan M.J., Spano P.F., Missale C. Pre-synaptic dopamine D3 receptor mediates cocaine-induced structural plasticity in mesencephalic dopaminergic neurons via ERK and Akt pathways. J. Neurochem. 120:765-778, 2012.
• Bellucci A, Navarria L, Falarti E, Zaltieri M, Bono F, Collo G, Spillantini MG, Missale C, Spano PF. Redistribution of DAT/α-synuclein complexes visualized by "in situ" proximity ligation assay in transgenic mice modelling early Parkinson's disease. PLoS One 6(12):e27959, 2011.
• Fiorentini C, Mattanza C, Collo G, Savoia P, Spano PF., Missale C. The tyrosine phosphatase SHP-2 interacts with the dopamina D1 receptor and triggers D1-mediated ERK signaling in striatal neurons. J. Neurochem. 117:253-63, 2011.
• Missale C, Fiorentini C, Collo G, Spano PF. The neurobiology of dopamine receptors: evolution from the dual concept to heterodimers complexes. J Recept Signal Transduct Res. 30: 347-54, 2010.
• Collo G*, Gregorini A, Missale C, Spano PF. D3 receptor involvement in neurotrophic effects of amphetamine and cocaine on mesencephalic dopaminergic neurons. European Neuropsychopharmacology 18:S243-S244. 2008.
• Collo G*, Zanetti S, Missale C, Spano PF. Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation Eur. J. Neurosci. 28:1231-1240, 2008.
• Bellucci A, Collo G, Sarnico I, Battistin L, Missale C, Spano PF. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation. J. Neurochem. 106:560-77. 2008.
• Collo G*, Goffi F, Merlo Pich E, Balzelli P, Benfenati F, Spano PF. Immature neuronal phenotype derived from mouse skin precursor cells differentiated in vitro. Brain Res.1109:32-36. 2006.
• Missale C, Fiorentini C, Busi C, Collo G, Spano PF. The NMDA/D1 receptor complex as a new target in drug development. Curr Top Med Chem. 6:801-808. 2006.
• Fiorentini C, Rizzetti MV, Busi C, Bontempi S, Collo G, Spano PF, Missale C. Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat. Mol. Pharmacol. 69:805-812. 2005.
• Mutini C, Falzoni S, Ferrari D, Chiozzi P, Morelli A, Baricordi OR, Collo G, Ricciardi-Castagnoli P, Di Virgilio F. Mouse dendritic cells express the P2X7 purinergic receptor: characterization and possible participation in antigen presentation. Journal of Immunology 163: 1958-65. 1999.
• Collo G, Pepper MS. Endothelial cell integrin alpha5beta1 expression is modulated by cytokines and during migration in vitro. Journal of Cell Science 112: 569-78. 1999.
• Buell G, Chessell IP, Michel AD, Collo G, Salazzo M, Herren S, Gretener D, Grahames C, Kaur R, Kosco-Vilbois MH, Humphrey PP. Blockade of human P2X7 receptor function with a monoclonal antibody. Blood 92: 3521-8. 1998.
• Brancaccio M, Cabodi S, Belkin AM, Collo G, Koteliansky VE, Tomatis D, Altruda F, Silengo L, Tarone G. Differential onset of expression of alpha7 and beta1D integrins during mouse heart and skeletal muscle development. Cell Adhesion and Commununication 5: 193-205. 1998.
• Russo S, Tomatis D, Collo G, Tarone G, Tato F. Myogenic conversion of NIH3T3 cells by exogenous MyoD family members: dissociation of terminal differentiation from myotube formation. Journal of Cell Science 111: 691-700. 1998.
• Ferrari D, Chiozzi P, Falzoni S, Dal Susino M, Collo G, Buell G, Di Virgilio F. ATP mediated cytotoxicity in microglial cells. Neuropharmacology 36: 1295-301. 1997.
• Collo G, Neidhart S, Kawashima E, Kosco-Vilbois M, North RA, Buell G. Tissue distribution of the P2X7 receptor. Neuropharmacology 36: 1277-83. 1997.
• Chiozzi P, Sanz JM, Ferrari D, Falzoni S, Aleotti A, Buell GN, Collo G, Di Virgilio F. Spontaneous cell fusion in macrophage cultures expressing high levels of the P2Z/P2X7 receptor. Journal Cell Biology 138: 697-706, 1997.
• Rassendren F. Buell GN. Virginio C. Collo G. North RA. Surprenant A. The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. Journal Biological Chemistry 272: 5482-6, 1997.
• Velling T. Collo G. Sorokin L. Durbeej M. Zhang H. Gullberg D. Distinct alpha7A-beta1 and alpha7B-beta1 integrin expression patterns during mouse development: alpha7A is restricted to skeletal muscle but alpha7B is expressed in striated muscle, vasculature, and nervous system. Developmental Dynamics 207: 355-71, 1996.
• Buell G. Collo G. Rassendren F. P2X receptors: an emerging channel family. European Journal of Neuroscience 8: 2221-8, 1996.
• Collo G. North RA. Kawashima E. Merlo-Pich E. Neidhart S. Surprenant A. Buell G. Cloning of P2X5 and P2X6 receptors and the distribution and properties of an extended family of ATP-gated ion channels. Journal of Neuroscience 16: 2495-507, 1996.
• Buell G. Michel AD. Lewis C. Collo G. Humphrey PP. Surprenant A. P2X1 receptor activation in HL60 cells. Blood 87: 2659-64, 1996.
• Buell G. Lewis C. Collo G. North RA. Surprenant A. An antagonist-insensitive P2X receptor expressed in epithelia and brain. EMBO Journal.15: 55-6, 1996.
• Collo G., Domanico S., Klier, G., and Quaranta, V. Gradient of integrin α6A expession in the myocardium during early heart development. Cell Adhesion and Communication 3: 101-13, 1995.
• Collo, G., Starr, L., and Quaranta, V. A new isoform of the laminin receptor α7β1 is developmentally regulated in skeletal muscle. Journal of Biological Chemistry 268: 19019-19024, 1993.
• Tamura, R.N., Cooper, H.M., Collo, G. and Quaranta, V. Cell-type specific integrin variants with alternative chain cytoplasmic domain. P. Natl. Acad. Sci. 88: 10183-10187, 1991.
• Quaranta V, Collo G, Rozzo C, Starr L, Gaietta G and Tamura RN The integrin alpha6beta4 in epithelial and carcinoma cells, In: Integrins: The Biological Problems Eds. Y Takada, CRC Press (Boca Raton) 147-176, 1994.
• Quaranta V, Tamura RN, Collo G, Cooper HM, Hormia M, Rozzo C, Gaietta G and Starr L. Distinctive functions of alpha6beta4 and other integrins in epithelial cells, In: Integrins: Molecular and Biological Responses to the Extracellular Matrix Eds. D Cheresh, M RP, Academic Press (San Diego) 141-161, 1994.